High bad and bcl-xL gene expression and combined bad, bcl-xL, bax and bcl-2 mRNA levels:: Molecular predictors for survival of stage 2 soft tissue sarcoma patients

被引:0
|
作者
Köhler, T
Würl, P
Meye, A
Lautenschläger, C
Bartel, F
Borchert, S
Bache, M
Schmidt, H
Holzhausen, HJ
Taubert, H
机构
[1] Univ Halle Wittenberg, Inst Pathol, D-06097 Halle An Der Saale, Germany
[2] Univ Leipzig, Inst Lab Med Clin Chem & Mol Diagnost, Leipzig, Germany
[3] Univ Leipzig, Clin Surg 1, Leipzig, Germany
[4] Univ Halle Wittenberg, Inst Med Biometry & Informat, D-06097 Halle An Der Saale, Germany
[5] Univ Halle Wittenberg, Dept Radiotherapy, D-06097 Halle An Der Saale, Germany
[6] Univ Dresden, Urol Clin, Dresden, Germany
关键词
soft tissue sarcoma; prognostic markers; bad; bax; bcl-xL bcl-2; mRNA expression; quantitative; high-throughput RT-PCR; 5 ' nuclease assay; DNA-coated strips;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The role of the bcl-2 gene family members in promoting or antagonizing apoptosis in malignant tumors, including soft tissue sarcomas (STS), is well known. However, the impact of mRNA expression of bcl-2 family genes on prognosis has not been thoroughly investigated in STS. Samples from 82 STS patients were analyzed for mRNA expression of bad, bax, bcl-x(L) and bcl-2 by a high-throughput quantitative RTPCR approach, using validated assays based on TaqMan(R) technology. The mRNA data, related to glyceraldehyde-3-phosphate dehydrogenase expression measured in the same sample, were analysed for their correlation to tumor stage and overall survival of patients. In a Kaplan-Meier analysis none of the mRNA levels investigated differed significantly with regard to their impact on survival (log-rank test). However, after including the tumor stage in the statistical analysis, a borderline significance was observed for bad mRNA expression (p=0.068) indicating a stage-specific impact of mRNA expression on prognosis. Considering STS patients of tumor stage 2, multivariate Cox analysis revealed that bad mRNA values greater than or equal to10 (p=0.0039; RR=9.08), bcl-x(L) greater than or equal to1.5 (p=0.067; RR = 4.59), bax greater than or equal to0.005 (p=0.1; RR=2.84) and bcl-2 <3 (p=0.42; RR=1.7) were associated with a poor prognosis. Combined high bad/bcl-x(L) mRNA expression levels revealed a 20 fold increase in the relative risk of tumor-related death (p=0.016) when comparing the poor and good prognosis groups. There was a 14.5 fold and 6.5-fold increase in the risk for the combinations of high bax/bcl-x(L) mRNA (p=0.018) and bax/bcl-2 mRNA expression (p=0.017), respectively. In conclusion, high bad mRNA levels and combined values of bad/bcl-x(L), bax/bcl-x(L) and bax/bcl-2 appear to be independent prognostic factors at least for stage 2 STS patients. In the combinations of mRNA levels there was more than an additive effect pointing to different pathways of prognostic relevance.
引用
收藏
页码:1553 / 1559
页数:7
相关论文
共 50 条
  • [1] Heterodimerization of Bcl-2 and BcL-XL with Bax and Bad in colorectal cancer
    Hattori, T
    Ookawa, N
    Fujita, R
    Fukuchi, K
    [J]. ACTA ONCOLOGICA, 2000, 39 (04) : 495 - 500
  • [2] The expression of Bcl-2, bax, Bcl-xl and bad in the human term placenta after hypoxia and reoxygenation
    Hung, T. H.
    Hsieh, T. T.
    [J]. PLACENTA, 2006, 27 (9-10) : A26 - A26
  • [3] Bcl-2, bax, bcl-xL and bcl-xS expression in neoplastic and normal cervical tissue
    Ferrandina, G
    Mozzetti, S
    Marone, M
    Fagotti, A
    Macchia, G
    Mancuso, S
    Scambia, G
    [J]. CANCER LETTERS, 2000, 155 (01) : 19 - 27
  • [4] Apoptosis and expression of Bcl-2, Bcl-XL, and Bax in renal cell carcinomas
    Gobé, G
    Rubin, M
    Williams, G
    Sawczuk, I
    Buttyan, R
    [J]. CANCER INVESTIGATION, 2002, 20 (03) : 324 - 332
  • [5] Bcl-2, Bax, Bcl-xL and Bcl-xS expression in neoplastic and normal endometrium
    Marone, M
    Ferrandina, G
    Macchia, G
    Mozzetti, S
    de Pasqua, A
    Benedetti-Panici, P
    Mancuso, S
    Scambia, G
    [J]. ONCOLOGY, 2000, 58 (02) : 161 - 168
  • [6] Expression of bcl-2, bax, bcl-xL, and bcl-xS, in endometrial and cervical tissues
    Mozzetti, S
    Ferrandina, G
    Marone, M
    D'Ingiullo, F
    Fruscella, E
    De Pasqua, A
    Mancuso, S
    Scambia, G
    [J]. CANCER DETECTION AND PREVENTION, 2000, 24 (06): : 536 - 541
  • [7] A brewing understanding of the regulation of Bax function by Bcl-xL and Bcl-2
    Renault, Thibaud T.
    Dejean, Laurent M.
    Manon, Stephen
    [J]. MECHANISMS OF AGEING AND DEVELOPMENT, 2017, 161 : 201 - 210
  • [8] EXPRESSION OF BCL-2 AND BCL-XL IN BREAST-CANCER
    CARROLL, AG
    LIPPMAN, ME
    [J]. MOLECULAR BIOLOGY OF THE CELL, 1995, 6 : 1439 - 1439
  • [9] Expression Of Bcl-2, Bax and Bcl-xl in Human Gliomas: A Re-appraisal
    Stéphane Martin
    Claire Toquet
    Lisa Oliver
    Pierre-François Cartron
    Pascale Perrin
    Khaled Meflah
    Paulette Cuillère
    François M. Vallette
    [J]. Journal of Neuro-Oncology, 2001, 52 : 129 - 139
  • [10] Expression of bcl-2, bax and bcl-xl in human gliomas:: A re-appraisal
    Martin, S
    Toquet, C
    Oliver, L
    Cartron, PF
    Perrin, P
    Meflah, K
    Cuillère, P
    Vallette, FM
    [J]. JOURNAL OF NEURO-ONCOLOGY, 2001, 52 (02) : 129 - 139